Chronic Antigen Stimulation in Solid Tumors Induces T Cell Exhaustion and Limits Efficacy of T Cell Bispecific Therapies
Idil Hutter-KarakociD, Eleni Maria Varypataki, Aparna Neelakandhan, Simone Lang, Vesna Kramar, Ahmet VaroliD, Sasha Simons, Marine RichardiD, Mudita Pincha, Dario Venetz, Nicole JolleriD, Christian MünziD, Pablo UmañaiD, Christian KleiniD, Maria AmanniD
Abstract
T cell bispecific antibodies (TCBs) have demonstrated promising results in patients with solid tumors. However, the underlying immunological and molecular mechanisms influencing these clinical outcomes require in depth evaluation. T cell exhaustion, a state induced by prolonged antigen exposure, is known to undermine T cell-based immunotherapies, though its specific impact on TCB efficacy remains unclear. In this study, we assessed the effectiveness of TCBs on tumor-specific T cells, focusing on their functional status. Utilizing a fully immunocompetent mouse model with a solid tumor expressing an immunogenic antigen, we showed that tumor-specific T cells acquire an exhausted phenotype and fail to expand under TCB treatment. By employing both mouse and human tumor-specific T cells in vitro, our study established that chronically stimulated tumor-specific T cells show impaired response to TCB treatment. The comparison of TCB efficacy in T cell-inflamed tumors with immunogenic antigens versus non-inflamed tumors with low antigen presence in mice revealed TCB success in solid tumors is more reliant on T cell functional fitness than on their abundance before treatment. The data also indicate that solid tumors with elevated levels of both, intratumoral regulatory T cells, and T cells expressing co-inhibitory receptors, show diminished responses to TCB therapy, aligning with similar observations described in hematological cancers. These findings highlight the critical role of T cell exhaustion due to chronic antigen exposure and illustrate that exhausted tumor-specific T cells are likely not the driver population redirected by TCBs for tumor elimination. Our research highlights the importance of maintaining T cell fitness and preventing T cell exhaustion to improve TCB therapy outcomes. This may help better identify patient populations with solid tumors that could benefit from TCB treatments most in clinical settings.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Bivalent bispecific CD28 antibodies reinforce T-cell responsiveness and revert anergy/quiescence in patients treated with bispecific CD3 antibodies
Latifa Zekri, Natalie Köhler, … Helmut Rainer Salih·bioRxiv·Sep 20, 2026
- Tumor-Specific CD8+ T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating Lymphocytes
E. M. Zawidzka, L. Biavati, … I. Borrello·bioRxiv·Aug 28, 2023
- Overcoming Tumor Heterogeneity by Ex Vivo Arming of T Cells Using Multiple Bispecific Antibodies
N.-K. Cheung, J. A. Park·bioRxiv·Aug 31, 2021
- In vivo screening of TCR-based chimeric antigen receptors for improved anti-tumor functionality
Andreas Zingg, Reto Ritschard, … Heinz Philipp Laubli·bioRxiv·Jul 23, 2025
- T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T-cells
Matthias Obenaus, Clara L. Poupault, … K. Christopher García·bioRxiv·Jan 27, 2026
- LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy
Robert Weldon Barnes, Archana B. Thakur, … Sepideh Dolatshahi·The Journal of ImmunologyPeer-reviewed·Aug 7, 2025